Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 236-237 , May 2009

Hypoxia inducible factor (HIF): Its central role in renal cell cancer targeted therapy

References 

  1. Gollob JA. Sorafenib: Scientific rationale for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourinary Cancer. 2005;4:167–174
  2. Michaelson MD, Iliopoulos O, McDermott DF, et al. Case 17-2008: A 63 year-old man with metastatic renal-cell carcinoma. New Eng J Med. 2008;358:2389–2396
  3. Gnarro JR, Tory K, Weng Y, et al. Mutation of the VHL tumor suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90
  4. Iliopoulos O, Kibel A, Gray S, et al. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1:822–826
  5. Kalein WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10:6920S–6925S
  6. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent protedysis. Nature. 1999;399:271–275

PII: S1078-1439(08)00222-6

doi: 10.1016/j.urolonc.2008.08.006

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 236-237 , May 2009

Article Tools

* Image Usage & Resolution